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Editorial
The national media have recently put intravenous (IV) hydra-
tion therapy and IV vitamins back in the spotlight. NBC’s 
Today Show recently aired a story on the opening of a new-age, 
direct-pay, boutique-style infusion clinic or spa, where custom-
ers can go in to receive a variety of on-demand IV cocktails 
that contain vitamins, trace elements, gastric acid–reducing 
drugs, or prescription nonsteroidal anti-inflammatory drugs 
mixed in saline or Lactated Ringer’s solution.1,2 This is a fast 
booming business with over a dozen new spas and “clinics” 
opening in major cities such as New York City, Los Angeles, 
Atlanta, Chicago, Scottsdale, Tampa, and Miami coming this 
fall.3-5 In some cities, such as Las Vegas and New Orleans, IV 
cocktails can be ordered ahead of time and delivered to your 
hotel room. Customers can also receive “treatment” in a mobile 
“clinic,” which is essentially a bus. The claims for these hydra-
tion remedies range from antiaging, improving athletic perfor-
mance, fighting a cold or flu, to treating a hangover. Under 
normal circumstances, the commentary section of the Journal 
of Parenteral and Enteral Nutrition (JPEN), the American 
Society for Parenteral and Enteral Nutrition’s premier scien-
tific journal of nutrition and metabolic support, is the perfect 
medium to deliberate about and debate on the scientific merit 
of IV hydration therapy. But this is no ordinary time.
We are in the middle of a critical IV drug shortage crisis, 
which the national media have failed to adequately address. As 
we write this commentary, critical nutrients such as parenteral 
trace elements, zinc, selenium, copper, multiple vitamin infu-
sion, potassium phosphate, potassium chloride, sodium ace-
tate, sodium phosphate, vitamin K, and cyanocobalamin, many 
of which are now being given at these hydration centers, are 
still in severe national shortages.6 Even Lactated Ringer’s solu-
tion and sodium chloride 0.9% are in critically short supply to 
a point that the U.S. Food and Drug Administration (FDA) is 
exercising its discretion to temporarily allow the importation 
of saline products from other countries to mitigate this crisis, 
which itself poses a serious threat to patients.7,8 Therefore, as 
journal editors, care providers, researchers, educators, and 
public policy advocates, we must address this disconnect 
between free access and the reality of scarce resources. At the 
present time, the ethical and safety aspects appear to have a 
more significant implication than the science in this issue.
The Ethics of Prescription Drug Use for 
Unproven and Unlikely Effective Purposes
Under U.S. law, IV hydration solutions (eg, sodium chloride 
0.9%), electrolytes, vitamins, and trace minerals are prescrip-
tion drugs rather than food, dietary supplements, or supplies. 
Their use and distribution are regulated by law for medical pur-
poses. The claim of using these prescription drugs for unproven 
purposes, such as hangovers and colds, over established medi-
cal needs, such as use in parenteral nutrition (PN) admixtures 
for patients with short bowel syndrome or other malabsorption 
syndromes, or in preterm neonates, especially during product 
shortages, should raise serious concern.
In these clinic or spa businesses, it is unclear who is ulti-
mately responsible for prescribing these medications. Some of 
these businesses are owned and registered under a licensed 
medical professional who has prescriptive authority. But it is 
unclear if the licensed prescriber is actually involved in the 
assessment or “treatment” of the customers who requested the 
IV cocktails. Other venues, such as a medical clinic at the 
553233 PENXXX10.1177/0148607114553233Journal of Parenteral and Enteral NutritionChan et al
research-article2014
From the 1School of Pharmacy and Graduate Program in Nutritional 
Sciences, School of Public Health, University of Washington, Seattle; 
2Department of Medicine, Columbia University, New York, New 
York; 3Mt Carmel West Hospital, Columbus, Ohio; 4American Society 
for Parenteral and Enteral Nutrition, Silver Spring, Maryland; 5Ohio 
Northern University, Nationwide Children’s Hospital, Columbus, 
Ohio; and 6Department of Surgery, University of Michigan, Ann 
Arbor.
This paper has been endorsed by the A.S.P.E.N. 2014-2015 Board of 
Directors.
Financial disclosure: None declared.
Conflicts of interest: D.H.T. and A.M. serve on the A.S.P.E.N. Board of 
Directors. L.N.C. is an associate editor for JPEN.
Received for publication September 3, 2014; accepted for publication 
September 5, 2014.
Corresponding Author:
Lingtak-Neander Chan, PharmD, BCNSP, CNSC, School of Pharmacy, 
University of Washington, Box 357630, 1959 NE Pacific Street, HSC, 
H361B, Seattle, WA 98195-7630, USA. 
Email: neander@u.washington.edu
Hangover and Hydration Therapy in the Time of 
Intravenous Drug Shortages: An Ethical Dilemma  
and a Safety Concern
Lingtak-Neander Chan, PharmD, BCNSP, CNSC1; David S. Seres, MD, ScM, PNS2; 
Ainsley Malone, MS, RD, CNSD3; Beverly Holcombe, PharmD, BCNSP, FASHP4; 
Peggi Guenter, PhD, RN, FAAN4; Steve Plogsted, PharmD, BCNSP, CNSC5;  
and Daniel H. Teitelbaum, MD6
922 Journal of Parenteral and Enteral Nutrition 38(8)
McCarran Las Vegas International Airport, is a full medical 
staff urgent care clinic with a licensed pharmacy where hang-
over therapy is also provided.9-11 It is appropriate to ask whether 
this is a proper use of prescription drugs. This is especially con-
cerning when some of the cocktails include prescription drugs 
such as ketorolac and lidocaine, which can lead to life-threaten-
ing adverse events in patients at risk. Some of these IV cocktails 
even contain substances, such as glutathione, that have never 
been approved by the FDA as an IV product.
The Ethics of Drug Acquisition and 
Distribution
With the critical shortages of maintenance IV fluids, electro-
lytes, and micronutrients, an obvious question is how these 
boutique infusion clinics and spas procure these substances. 
Most of these business entities are unwilling to disclose the 
sources where their products are purchased or prepared.12 Are 
these businesses procuring these products through the gray or 
even black markets, or are they competing with healthcare 
facilities for the national supply of fluids and nutrients? In fact, 
over the past 5 years, while many patients were unable to be 
given some of these critical nutrients, the same nutrients were 
delivered to customers at these unregulated therapy venues. By 
doing so, they might have greatly exacerbated the problem 
with IV drug shortages and possibly depleted our national sup-
ply of fluids and nutrients that are much needed by patients 
who have no other alternative.
Some reports suggest that the suppliers for these boutique 
clinics are compounding pharmacies or non–U.S.-registered 
pharmaceutical suppliers.12 What are the mechanisms to ensure 
the quality of these compounded products or non–FDA-
approved drugs? Legally classified as prescription drugs, IV 
fluids, electrolytes, vitamins, and micronutrients are regulated 
under the Prescription Drug Marketing Act of 1987, which was 
enacted to (a) ensure that drug products purchased by consum-
ers are safe and effective and (b) avoid the unacceptable risk to 
U.S. consumers from counterfeit, adulterated, misbranded, 
subpotent, or expired drugs.13 When compounded or non–
FDA-approved products are used, what is the mechanism to 
safeguard the recipients from receiving products that are sub-
potent, chemically unstable, physically incompatible, adulter-
ated, misbranded, or even placebos?
If the compounding pharmacies are functioning as outsourc-
ing facilities, are their operations in compliance with state and 
federal laws and regulations, including USP <797> and the 
Compounding Quality Act of 2013?14 Are properly trained or 
certified personnel involved in the preparation and inspection of 
their parenteral products prior to delivery? Are the compounded 
products properly labeled and stored at optimal temperature with 
a valid use-by date at both the compounding pharmacies and the 
boutique clinics? These are serious issues that must be addressed 
so that another outbreak of diseases due to product contamina-
tion, similar to the fungal meningitis outbreak in Massachusetts 
2 years ago that led to more than 60 deaths, will not be repeated.15
We must keep in mind that although this business model is 
relatively new, the use of vitamin/mineral-fortified IV fluids 
for nonessential purposes continues amid the ongoing national 
IV drug shortages. We continue to hear reports about how IV 
micronutrients, such as Myer’s Cocktail and other IV vitamin 
therapy regimens (most containing high doses of ascorbic acid 
and zinc), are administered to many professional athletes and 
celebrities on a regular basis, while practitioners are scram-
bling to find intermittent supplies for PN-dependent 
patients.12,16 At the same time, more reports of patients devel-
oping clinical micronutrient deficiencies associated with IV 
drug shortages have been published in the past 2 years.17-22 It is 
unclear how many and how often these businesses compete 
with hospitals, medical clinics, and home infusion companies 
for the same distributors in ordering and stockpiling these 
FDA-approved prescription medications. With the continued 
challenge of IV fluid, electrolyte, and micronutrient shortages 
we are facing in patient care, there are still no rules, regula-
tions, or even incentives for putting patients’ benefits ahead of 
business interests and corporate profits. It is unfortunate that 
the law to allow access to affordable care has been passed but 
the resource to deliver the most basic level of care, such as an 
IV saline solution with potassium, cannot be guaranteed in 
patients with the most need.
Additional Concerns for Non–FDA-
Approved Products
If the supply chain for these practices is not in direct competi-
tion with the national drug supply for patients, further assess-
ment of their supply sources and practice should be conducted. 
The suppliers for these businesses should be disclosed. 
Customers should be followed up for any adverse events, as 
well as complications related to their infusions, and visits to 
the emergency department or urgent care clinic should be 
reported. After all, IV infusion therapy is an established medi-
cal procedure with designated Current Procedural Terminology 
(CPT) codes. All the recipients of these IV drugs should there-
fore be entitled to the same level of care and scrutiny for safety 
provided by their providers.
With proper legislation and monitoring, it is possible that 
some of these business practices may become partners of 
healthcare researchers in resolving the IV drug shortage crisis. 
We can establish minimum standards for safe practices with 
regard to staffing, drug preparation and administration, and 
follow-up care in these venues. Those who meet the minimum 
standards may become licensed facilities, where safety data 
related to the non–FDA-approved products will be collected 
and evaluated. The sources of the products will be tracked and 
routine testing for product consistency will be performed. 
Agencies and researchers should be given an open source to 
track these data. This may potentially help the FDA identify 
and prioritize additional products that can be further reviewed 
for approval or compounding pharmacies that may be certified 
to supply a limited number of products locally for patients.
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An Issue Close to Home
With the increased access to these business entities, the con-
cerns raised above are not hypothetical and may have already 
hit home. Consider that one of our PN-dependent patients has 
utilized an IV boutique clinic for his vitamins and trace ele-
ments because the home infusion company is in short supply. 
Was his IV site manipulated by a trained healthcare provider? 
Was proper aseptic technique used? What did the patient actu-
ally receive? Did the product contain contaminants or other 
impurities? Were the specific ingredients infused contraindi-
cated in this patient? What if your patient has already devel-
oped symptoms related to micronutrient deficiency and wants 
your advice? Would you take a chance? Would you be able to 
convince your patient to not take a chance? These are very 
challenging ethical and safety issues that cannot be addressed 
without legislative changes and collaboration among individu-
als with different interests.
In this long-running drug shortage crisis with no apparent 
long-term resolution, boutique-style IV hydration therapy is an 
area we can no longer ignore because this business practice has 
an inseparable impact on IV drug shortage. Instead of viewing 
the business as villains, we may, with increased transparency 
and disclosure, legislative changes, and government oversight, 
find a new partner to take us a step closer in solving our com-
plex problems. We urge the FDA, national legislators, and the 
business representatives to act swiftly.
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